Investment: “Biolevate raises €30M”
Life sciences AI company Biolevate has raised €30 million in a Series A round co‑led by RAISE France, the investment vehicle of French entrepreneur Aymar Hénin, and Orange Ventures. The funding will expand its platform for automating scientific and regulatory workflows and support its international growth.
The round also included participation from MSD Global Health Innovation Fund (MGHIF), Station F and existing investor EQT Ventures.
Founded in Paris by a team of former Dataiku engineers and AI researchers, Biolevate has developed an enterprise agentic AI platform that turns scientific and regulatory knowledge into auditable workflows. The platform is designed to keep its outputs grounded in source evidence, allowing life sciences organisations to use AI in regulated environments while maintaining human oversight.
Initially developed to accelerate regulatory approval workflows, the platform now covers areas across the life sciences value chain including research, clinical trials, health technology assessments, regulatory dossiers, drug discovery and drug development, and can run up to 100,000 agents concurrently. Biolevate says it has accelerated systematic literature reviews and research synthesis sixteenfold and delivered an 80 per cent efficiency gain in regulatory intelligence and compliance. Since its seed round in 2024, it serves more than a dozen enterprise customers and has reported growth in annual recurring revenue.
The company says the Series A will be used to accelerate international expansion, deepen product capabilities and scale deployments with life sciences organisations. The Series A coincides with expansion into the US with an office opening in Boston; Biolevate doubled its headcount over the past year and expects to double again over the coming year. It has also drafted seven patent applications across several therapeutic areas, two of which have been filed in Europe.
We started Biolevate with a mission-driven team united by the belief that AI could improve millions of lives if we empowered the right people and solved the right technological challenges. Today, our vision is becoming reality. Customers are increasingly embracing AI automation at scale, grounded in evidence and under rigorous human oversight, said Joël Belafa, co-founder and CEO of Biolevate.
